Accessibility Menu
Haemonetics logo

Haemonetics(NYSE) HAE

Market Cap$3.99BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1991)+1,379%
5 Year+50%
1 Year+58%
1 Month+19%
$86.12
-1.96%
-1.72Today
Haemonetics last closing stock price
MetricPriceDate
Last closeUSD 87.842026-08-07
Haemonetics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+2.69%USD 85.542026-07-31
1 month+18.99%USD 73.822026-07-08
3 month+59.36%USD 55.122026-05-08
Year to date+9.59%USD 80.152025-12-31
1 year+57.9%USD 55.632025-08-07
3 year-2.33%USD 89.942023-08-08
5 year+50.21%USD 58.482021-08-06
Since inception+1,379.41%USD 5.941991-05-10

Haemonetics Financials at a Glance

Market Cap

$3.99BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$1.35B

Net Income (TTM)

$96.29M

EPS (TTM)

$2.05

P/E Ratio

42.84

Dividend

$0.00

Beta (Volatility)

0.73 (Low)

Price

$86.12

Volume

308,427.282

Open

$87.39

Previous Close

$87.84

Daily Range

$85.97 - $87.97

52-Week Range

$47.32 - $88.59

Estimated Earnings Date

Nov 5, 2026

HAE News

SellAlert-Red.png

What Investors Should Know About a $24 Million Exit From a Medical Device Stock Down 9% This Past Year

Jonathan PoncianoMar 20, 2026
institutional.png

SG Capital Dumps Nearly 732,000 Haemonetics Shares Worth $59.1 Million

Lawrence Rothman, CFANov 8, 2025
Person in a lab gazing into a microscope

Why Haemonetics Stock Was on Fire Thursday

Eric VolkmanNov 7, 2025
Foolcom-Featured.png

Haemonetics (HAE) Q1 Revenue Falls 4%

Motley Fool Markets TeamAug 7, 2025
Old and young male patient seated and conferring with a doctor

Why Haemonetics Stock Dived by 15% Today

Eric VolkmanNov 9, 2021
GettyImages-1204666796

Why Haemonetics Stock Rallied on Friday

Eric VolkmanMay 14, 2021
The hallway of a hospital

Why Haemonetics Stock Fell 13% Today

Eric VolkmanMay 13, 2021
P

Why Baidu, Pandora Media, and Haemonetics Slumped Today

Dan CaplingerMay 2, 2016
Page 1

HAE: Motley Fool Moneyball Superscore

66

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Haemonetics

Haemonetics makes tools and software that help clinics collect and manage blood and plasma safely.

These products help hospitals and blood centers treat patients and create life-saving medicines.

The company serves medical professionals who perform surgeries or manage donor collections.

Inside the Product Catalog

  • Hospital Technologies: Tools for vascular closure, esophageal protection, and hemostasis (blood clotting) analysis; accounted for 44.1% of revenue in fiscal 2026.
  • Plasma Systems: Automated collection devices and software used to gather source plasma for medicine; represented 39.3% of revenue in fiscal 2026.
  • Blood Center Products: Equipment for separating blood components and preparing red cells for transfusion; made up 16.6% of revenue in fiscal 2026.

Deals and Divestitures

  • Acquired Vivasure Medical Limited, OpSens Inc., and Attune Medical to expand its hospital and interventional technology portfolios.
  • Divested the Whole Blood product line in January 2025 to focus on higher-margin opportunities.
  • Received U.S. Food and Drug Administration (FDA) clearance for the NexSys PCS with Persona PLUS technology in the fourth quarter of fiscal 2026.
  • Expanded the use of the VASCADE MVP XL system for larger procedural sheaths following FDA approval in the fourth quarter of fiscal 2026.

Why the Company Stands Out

Haemonetics uses proprietary Persona technology to customize plasma collection based on an individual donor's specific body composition. The company maintains a direct sales force and distributors reaching approximately 90 countries to serve biopharmaceutical and hospital customers.

Key Financial Trends

  • Revenue reached $346.4 million in Q4 2026, up 4.8% from $330.6 million in Q4 2025.
  • Gross profit was $198.2 million in Q4 2026, up 9% from $181.9 million in the prior year.
  • Operating income was $51.4 million in Q4 2026, down 0.0% from $51.5 million in Q4 2025.
  • Net income reached -$20.1 million in Q4 2026, which worsened from $58 million in Q4 2025.
  • Free cash flow hit $53.3 million in Q4 2026, down 47.2% from $100.9 million in the previous year.

Bottom Line

Haemonetics is shifting its focus toward high-growth hospital and plasma technologies while exiting lower-margin blood collection markets. Its recent acquisitions and regulatory approvals signal a transition into more specialized medical device categories.

AI Generated • May 24, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

3,009

CEO

Christopher A. Simon, MBA

Website

www.haemonetics.com

Headquarters

Boston, MA 02110, US

HAE Financials

Key Financial Metrics (TTM)

Gross Margin

57.38%

Operating Margin

18.18%

Net Income Margin

7.12%

Return on Equity

11.35%

Return on Capital

11.95%

Return on Assets

4.07%

Earnings Yield

2.33%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$3.99BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

45.45M

Volume

308.43K

Avg. Volume

887.37K

Financials (TTM)

Gross Profit

$775.84M

Operating Income

$245.74M

EBITDA

$261.21M

Operating Cash Flow

$328.15M

Capital Expenditure

-$36.93M

Free Cash Flow

$291.22M

Cash & ST Invst.

$223.38M

Total Debt

$1.17B

Haemonetics Performance Analysis

Haemonetics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31USD 1,168,660,00017.7%
20242024-03-31USD 1,309,055,00012.0%
20252025-03-31USD 1,360,824,0004.0%
20262026-03-31USD 1,334,027,000-2.0%
Haemonetics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-09-271.8%
Q32025-12-273.6%
Q42026-03-282.2%
Q12026-06-27-2.0%
Haemonetics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31USD 2.24165.7%
20242024-03-31USD 2.291.9%
20252025-03-31USD 3.3144.5%
20262026-03-31USD 2.05-37.8%
Haemonetics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-09-2715.7%
Q32025-12-2717.3%
Q42026-03-28-146.3%
Q12026-06-27263.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2027YOY CHG

Revenue

$339.38M

+5.6%

Gross Profit

$202.80M

+5.7%

Gross Margin

59.76%

N/A

Market Cap

$3.99BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.33M

N/A

Employees

3,009

N/A

Net Income

$33.01M

-3.0%

EBITDA

$74.69M

-20.3%

Quarterly Fundamentals

Name
Q1 2027YOY CHG

Total Cash

$223.38M

-23.7%

Total Debt

$1.17B

-4.1%

Accounts Receivable

$216.07M

+7.6%

Inventory

$306.74M

-14.9%

Long Term Debt

$1.17B

+27.0%

Short Term Debt

$4.96M

-98.4%

Return on Assets

4.07%

N/A

Return on Invested Capital

11.69%

N/A

Free Cash Flow

$44.42M

+225.6%

Operating Cash Flow

$52.32M

+200.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CPRXCatalyst Pharmaceuticals, Inc.
$31.49+0.00%
ITGRInteger Holdings Corporation
$125.10-0.14%
CONConcentra Group Holdings Parent, Inc.
$33.93-0.38%
WRBYWarby Parker Inc.
$26.16-1.15%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$135.37+0.02%
ACHRArcher Aviation
$6.21+0.11%
NVDANvidia
$219.10-0.02%
ONDSOndas
$9.27+0.02%

Questions About HAE

What is the current price of Haemonetics?

Haemonetics is trading at $86.22 per share.

What is the 52-week range for Haemonetics?

Over the past 52 weeks, Haemonetics has traded between $47.32 and $88.59.

How much debt does Haemonetics have?

As of the most recent reporting period, Haemonetics reported total debt of $1.17B.

How much cash does Haemonetics have on hand?

Haemonetics reported $223.38M in cash and cash equivalents in its most recent financial results.

What is Haemonetics’s dividend yield?

Haemonetics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services